Sissy Peterman

1.6k total citations · 1 hit paper
16 papers, 1.3k citations indexed

About

Sissy Peterman is a scholar working on Genetics, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Sissy Peterman has authored 16 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 9 papers in Pathology and Forensic Medicine and 6 papers in Molecular Biology. Recurrent topics in Sissy Peterman's work include Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (9 papers) and Advanced Breast Cancer Therapies (5 papers). Sissy Peterman is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (9 papers) and Advanced Breast Cancer Therapies (5 papers). Sissy Peterman collaborates with scholars based in United States, Poland and France. Sissy Peterman's co-authors include Steven Coutré, Ian W. Flinn, Nina D. Wagner‐Johnston, Albert S. Yu, Stephen E. Spurgeon, Brad S. Kahl, Richard R. Furman, Jennifer R. Brown, Don M. Benson and Roger G. Ulrich and has published in prestigious journals such as Journal of Clinical Oncology and Blood.

In The Last Decade

Sissy Peterman

16 papers receiving 1.2k citations

Hit Papers

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase... 2014 2026 2018 2022 2014 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
    2014 465 citations Jennifer R. Brown, John C. Byrd et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sissy Peterman United States 14 1.1k 806 434 322 277 16 1.3k
Amber Gordon United States 8 1.2k 1.1× 792 1.0× 432 1.0× 535 1.7× 340 1.2× 14 1.5k
Priti Patel United States 17 841 0.8× 699 0.9× 261 0.6× 301 0.9× 269 1.0× 57 1.2k
John N. Allan United States 21 803 0.8× 708 0.9× 206 0.5× 319 1.0× 333 1.2× 97 1.1k
Sara Rodríguez United States 5 758 0.7× 659 0.8× 162 0.4× 238 0.7× 255 0.9× 12 913
Kathryn Humphrey United Kingdom 16 1.0k 1.0× 920 1.1× 208 0.5× 369 1.1× 433 1.6× 52 1.4k
Olga Samoilova Russia 9 574 0.5× 634 0.8× 198 0.5× 179 0.6× 388 1.4× 20 912
Annette Ervin‐Haynes United States 12 438 0.4× 700 0.9× 278 0.6× 98 0.3× 553 2.0× 42 986
Kerstin Allen United States 13 467 0.4× 472 0.6× 261 0.6× 248 0.8× 198 0.7× 18 754
Marwan Kwok United Kingdom 10 522 0.5× 422 0.5× 320 0.7× 277 0.9× 288 1.0× 15 881
Margaret S. Lucas United States 15 1.2k 1.1× 955 1.2× 209 0.5× 610 1.9× 254 0.9× 34 1.5k

Countries citing papers authored by Sissy Peterman

Since Specialization
Citations

This map shows the geographic impact of Sissy Peterman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sissy Peterman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sissy Peterman more than expected).

Fields of papers citing papers by Sissy Peterman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sissy Peterman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sissy Peterman. The network helps show where Sissy Peterman may publish in the future.

Co-authorship network of co-authors of Sissy Peterman

This figure shows the co-authorship network connecting the top 25 collaborators of Sissy Peterman. A scholar is included among the top collaborators of Sissy Peterman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sissy Peterman. Sissy Peterman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Jones, Jeffrey A., Tadeusz Robak, Małgorzata Wach, et al.. (2016). Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 34(15_suppl). 7515–7515. 13 indexed citations
2.
Coutré, Steven, John P. Leonard, Christopher R. Flowers, et al.. (2015). Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM).. Journal of Clinical Oncology. 33(15_suppl). 8532–8532. 4 indexed citations
3.
Jones, Jeffrey A., Małgorzata Wach, Tadeusz Robak, et al.. (2015). Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 33(15_suppl). 7023–7023. 19 indexed citations
4.
Flinn, Ian W., Brad S. Kahl, John P. Leonard, et al.. (2014). Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 123(22). 3406–3413. 167 indexed citations
5.
Brown, Jennifer R., John C. Byrd, Steven Coutré, et al.. (2014). Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 123(22). 3390–3397. 465 indexed citations breakdown →
6.
Kahl, Brad S., Stephen E. Spurgeon, Richard R. Furman, et al.. (2014). A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 123(22). 3398–3405. 199 indexed citations
7.
Benson, Don M., Brad S. Kahl, Richard R. Furman, et al.. (2013). Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL).. Journal of Clinical Oncology. 31(15_suppl). 8526–8526. 12 indexed citations
8.
Eradat, Herbert, Steven Coutré, Jacqueline C. Barrientos, et al.. (2013). A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 31(15_suppl). TPS7133–TPS7133. 17 indexed citations
9.
Spurgeon, Stephen E., Nina D. Wagner‐Johnston, Richard R. Furman, et al.. (2013). Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL).. Journal of Clinical Oncology. 31(15_suppl). 8519–8519. 14 indexed citations
10.
Brown, Jennifer R., Richard R. Furman, Ian W. Flinn, et al.. (2013). Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL.. Journal of Clinical Oncology. 31(15_suppl). 7003–7003. 37 indexed citations
11.
12.
Coutré, Steven, John C. Byrd, Richard R. Furman, et al.. (2011). Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110d, in patients with previously treated chronic lymphocytic leukemia.. Journal of Clinical Oncology. 29(15_suppl). 6631–6631. 60 indexed citations
13.
14.
15.
16.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amber Gordon Breakdown of academic impact, for papers by Priti Patel Breakdown of academic impact, for papers by John N. Allan Breakdown of academic impact, for papers by Sara Rodríguez Breakdown of academic impact, for papers by Kathryn Humphrey Breakdown of academic impact, for papers by Olga Samoilova Breakdown of academic impact, for papers by Annette Ervin‐Haynes Breakdown of academic impact, for papers by Kerstin Allen Breakdown of academic impact, for papers by Marwan Kwok Breakdown of academic impact, for papers by Margaret S. Lucas
Rankless by CCL
2026